
NYSE:UNH
This summary was created by AI, based on 41 opinions in the last 12 months.
UnitedHealth Group Inc. (UNH) has been facing a tumultuous year, experiencing significant operational challenges and regulatory scrutiny, particularly concerning Medicare funding and rising medical costs. Despite the negative sentiment surrounding the stock, several analysts maintain a long-term optimistic outlook, believing in the company's potential for recovery as the new CEO implements strategic changes. Notably, many experts express concerns regarding overstated revenues and the pressures from an aging U.S. population, which could impact margins for the foreseeable future. Analysts variedly highlight the stock's current valuation and future growth potential, with some viewing it as undervalued due to anticipated earnings recovery. Overall, the sentiment remains mixed as the company navigates complex market dynamics, yet some analysts see long-term opportunities for patient investors.
The company came out with very strong earnings – 12% growth y-o-y. Despite the run in share prices currently, he thinks there is still lots of runway. The companies touches on so many aspects of public health in the US and suggests politicians will avoid public cuts in spending going forward. He sees their growth continuing. Yield 1.3%.
(A Top Pick June 13/17 Up 29%) He sees no reason to move away from this holding. It is a consistent performer and will continue to do well. The independant gorilla in the Medicare and Medicaid space in the US. Did have a little bit of a pullback and consolidation. A very positive story and good momentum based on last quarter earnings.
Amazon, Berkshire Hathaway and J.P. Morgan just announced forming a healthcare company aimed at cutting costs. The experiment with government led healthcare mandates really didn’t work. There was far too much friction between opposing views. If you own the stock, you shouldn't get too excited about just one day, or the fact that insurers are going to go away.